Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now

Stock Information for Moleculin Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Moleculin Biotech Inc.

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial
Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update
Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast
Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
Moleculin to Present at the 37th Annual ROTH Conference
Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity
Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium
Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.